Fang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fang Wang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Degui Wang
Department of Anatomy and Histology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
2 shared publications Algahdary Omar Ahmed Omar Mariam
School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
1 shared publicationBaoliang Ma
Gansu Nephro-Urological Clinical Center, Key Laboratory of Urological Diseases, Gansu Province (Lanzhou University), Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou730000,China
1 shared publicationChao Wang
The First Clinical Medical College of Lanzhou University, Lanzhou, China
1 shared publicationChuan Zhou
The First Clinical Medical College of Lanzhou University, Lanzhou, China
1 shared publication- Feng-Hai Zhou
The First Clinical Medical College of Lanzhou University, Lanzhou, China
1 shared publication
Latest Publications
- Open Access
- 18 June 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-15
Precise prediction of bone metastases and metastatic burden using exosomal mirnas and radiomics: a multi-center study
Bone metastasis of prostate cancer (PCa) is a challenging problem, leading to poor prognosis of patients. Existing biomarkers have limited sensitivity and specificity. Therefore, we urgently need a novel diagnostic tool to predict PCa bone metastasis. Patient data and blood samples were collected according to the inclusion and exclusion criteria. logistic regression analysis was used to screen clinical indicators and miRNAs, and radiomics was used to construct a prediction model. Finally, the performance of the model was evaluated by internal verification, external verification and Delong test. Two nomograms were successfully established by analyzing clinical data, plasma miRNAs and imaging data. Nomogram 1 predicts the presence or absence of bone metastasis; Nomogram 2 predicts whether the number of bone metastases is ≥ 4. Nomogram 1 constructed by tPSA, hsa-miR-548o-3p and radiomics had an AUC of 0.904. The AUC of the internal training set was 0.879, the internal test set was 0.956, and the AUC of the external data set was 0.877. The calibration curve and decision curve all performed well. Nomogram 2 constructed by ALP, hsa-miR-548o-3p and radiomics had an AUC of 0.849, with an AUC of 0.916 in the internal training set, 0.806 in the internal test set and 0.839 in the external data set. The calibration curve and decision curve showed good performance. The combination of plasma exosomal miRNA and radiomics model has high reliability and accuracy in predicting the presence and number of bone metastases of PCa.
- 18 June 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-15
Open AccessPrecise prediction of bone metastases and metastatic burden using exosomal mirnas and radiomics: a multi-center study
Bone metastasis of prostate cancer (PCa) is a challenging problem, leading to poor prognosis of patients. Existing biomarkers have limited sensitivity and specificity. Therefore, we urgently need a novel diagnostic tool to predict PCa bone metastasis. Patient data and blood samples were collected according to the inclusion and exclusion criteria. logistic regression analysis was used to screen clinical indicators and miRNAs, and radiomics was used to construct a prediction model. Finally, the performance of the model was evaluated by internal verification, external verification and Delong test. Two nomograms were successfully established by analyzing clinical data, plasma miRNAs and imaging data. Nomogram 1 predicts the presence or absence of bone metastasis; Nomogram 2 predicts whether the number of bone metastases is ≥ 4. Nomogram 1 constructed by tPSA, hsa-miR-548o-3p and radiomics had an AUC of 0.904. The AUC of the internal training set was 0.879, the internal test set was 0.956, and the AUC of the external data set was 0.877. The calibration curve and decision curve all performed well. Nomogram 2 constructed by ALP, hsa-miR-548o-3p and radiomics had an AUC of 0.849, with an AUC of 0.916 in the internal training set, 0.806 in the internal test set and 0.839 in the external data set. The calibration curve and decision curve showed good performance. The combination of plasma exosomal miRNA and radiomics model has high reliability and accuracy in predicting the presence and number of bone metastases of PCa.
- 6 February 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (9) , 6315-6328
Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS–STING pathway
Purposes Increased number of studies reveal the crucial role of the Cyclic GMP–AMP synthase/stimulator of interferon genes (cGAS/STING) pathway in anti-tumor immunity. In this study, we aim to explore the effect of cGAS/STING on tumor immune microenvironment of melanoma after carbon ion radiotherapy (CIRT) and the underlying mechanism. Methods C57BL/6 mouse tumor models were used to evaluate the efficacy of different treatments (X-ray, carbon ion, PD-L1 inhibitor and combination therapies) on tumor growth and process. Mass cytometry was performed to assess tumor-infiltrating lymphocytes (TILs). DNA damage response (DDR) and cGAS/STING pathway were investigated by immunofluorescence-co-localization assays, γ-H2AX, P53-binding protein 1 (53BP1), Breast Cancer 1 (BRCA1), and cGAS measurements. Results Carbon ion irradiation caused more DNA damages and cGAS–STING pathway activation compared with X-ray irradiation, and the former slowed the melanoma growth in syngeneic model. Although X-ray irradiation is not sensitive for melanoma treatment, carbon ion irradiation showed a significant anti-tumor effect for melanoma treatment. TILs analysis revealed that CIRT boosted the infiltration of natural killer (NK), CD4+, and CD8+ T cells, meanwhile increased the number of immune checkpoint (programmed death-1, PD-1, lymphocyte activation gene 3, LAG-3 and T-cell immunoglobulin and mucin domain-containing protein 3, TIM-3). Moreover, CIRT increased PD-L1 exposure on cell surface compared with X-ray group. Furthermore, CIRT combined with PD-L1 inhibitor therapy increased the number of T cells and NK cells in melanoma, and slowed the growth of melanoma compared with other therapies. Conclusions Our findings showed that CIRT displayed biological effects by increasing DNA damages of tumor cells and improving immunity in melanoma, which indicated that CIRT might be a potential synergetic treatment for radiotherapy and radioimmunotherapy in melanoma patients. Our works put forward a new insight to provide an effective strategy for melanoma therapy. These findings may help in the design of strategies on melanoma in clinical studies.
- 6 February 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (9) , 6315-6328
Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS–STING pathway
Purposes Increased number of studies reveal the crucial role of the Cyclic GMP–AMP synthase/stimulator of interferon genes (cGAS/STING) pathway in anti-tumor immunity. In this study, we aim to explore the effect of cGAS/STING on tumor immune microenvironment of melanoma after carbon ion radiotherapy (CIRT) and the underlying mechanism. Methods C57BL/6 mouse tumor models were used to evaluate the efficacy of different treatments (X-ray, carbon ion, PD-L1 inhibitor and combination therapies) on tumor growth and process. Mass cytometry was performed to assess tumor-infiltrating lymphocytes (TILs). DNA damage response (DDR) and cGAS/STING pathway were investigated by immunofluorescence-co-localization assays, γ-H2AX, P53-binding protein 1 (53BP1), Breast Cancer 1 (BRCA1), and cGAS measurements. Results Carbon ion irradiation caused more DNA damages and cGAS–STING pathway activation compared with X-ray irradiation, and the former slowed the melanoma growth in syngeneic model. Although X-ray irradiation is not sensitive for melanoma treatment, carbon ion irradiation showed a significant anti-tumor effect for melanoma treatment. TILs analysis revealed that CIRT boosted the infiltration of natural killer (NK), CD4+, and CD8+ T cells, meanwhile increased the number of immune checkpoint (programmed death-1, PD-1, lymphocyte activation gene 3, LAG-3 and T-cell immunoglobulin and mucin domain-containing protein 3, TIM-3). Moreover, CIRT increased PD-L1 exposure on cell surface compared with X-ray group. Furthermore, CIRT combined with PD-L1 inhibitor therapy increased the number of T cells and NK cells in melanoma, and slowed the growth of melanoma compared with other therapies. Conclusions Our findings showed that CIRT displayed biological effects by increasing DNA damages of tumor cells and improving immunity in melanoma, which indicated that CIRT might be a potential synergetic treatment for radiotherapy and radioimmunotherapy in melanoma patients. Our works put forward a new insight to provide an effective strategy for melanoma therapy. These findings may help in the design of strategies on melanoma in clinical studies.
- 1 April 2021
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 21 (2) , 160-166
Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice
Background: In our previous studies, we had demonstrated the efficiency and specificity of constructed bladder tissue specific adenovirus Ad-PSCAE-UPII-E1A-AR (APU-EIA-AR) on bladder cancer, we also investigated the virus biodistribution and body toxicity in nude mice. However, the safety of the bladder cancer specific oncolytic adenovirus on fetal mice and F1 mice should be under intense investigation. Objectives: In order to evaluate the teratogenic toxicity of bladder cancer specific oncolytic adenovirus APU-EIA-AR on mice, in this study, we investigated the fetal mice weight, fetal body length and tail length, fetal skeleton development, as well as the F1 mice weight, growth curve, and major organ pathology. These teratogenic toxicity data of bladder tissue specific adenovirus AdPSCAE-UPII-E1A-AR (AD) would provide safe information prior to embarking on clinical trials. Methods: At sixth day of being fertilized, the pregnant mice began to be intramuscular administrated with AD (1×107VP, 1×108VP, 1×109VP) every other day for ten days. Then ,the pregnants were devided into two groups. One group was euthanized at seventeenth day, took out the fetal mice ,observing the bone structure of the infants. The oth er group was observed until natural childbirth. The Filial Generation (F1) are feeded and growth for 30 days, the variation in the growth progress and developmen t were assessed. Then the mice were euthenazied, the organ tissue were performed pathological section and HE staining, observing the changes under microscope. Results: In the process of teratogenic toxicity test , comparing with control group ,the Placenta weight ,fetal mice weight , body len gth and tail length of mice fetal in adenovirus treated group did not reveal any alteration. Comparing with PBS group, there is no obvious change in skeleton of fetal mice treated with adenovirus. During the development process of F1 mice treated with adenovirus, the changes of mice weight show statistical significance. Howerer, in the progress of growth curve, this difference is not very obvious. Furthermore, the pathological section showed no obvious alteration in major organs. Conclusion: Our study demonstrated that bladder cancer specific adenovirus Ad-PSCAE-UPII-E1A-AR appear safe in the pregnant mice without any discernable effects on fetal mice and F1 development. Hence, It is a relatively safe for tumor gene therapy.
- 1 April 2021
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 21 (2) , 160-166
Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice
Background: In our previous studies, we had demonstrated the efficiency and specificity of constructed bladder tissue specific adenovirus Ad-PSCAE-UPII-E1A-AR (APU-EIA-AR) on bladder cancer, we also investigated the virus biodistribution and body toxicity in nude mice. However, the safety of the bladder cancer specific oncolytic adenovirus on fetal mice and F1 mice should be under intense investigation. Objectives: In order to evaluate the teratogenic toxicity of bladder cancer specific oncolytic adenovirus APU-EIA-AR on mice, in this study, we investigated the fetal mice weight, fetal body length and tail length, fetal skeleton development, as well as the F1 mice weight, growth curve, and major organ pathology. These teratogenic toxicity data of bladder tissue specific adenovirus AdPSCAE-UPII-E1A-AR (AD) would provide safe information prior to embarking on clinical trials. Methods: At sixth day of being fertilized, the pregnant mice began to be intramuscular administrated with AD (1×107VP, 1×108VP, 1×109VP) every other day for ten days. Then ,the pregnants were devided into two groups. One group was euthanized at seventeenth day, took out the fetal mice ,observing the bone structure of the infants. The oth er group was observed until natural childbirth. The Filial Generation (F1) are feeded and growth for 30 days, the variation in the growth progress and developmen t were assessed. Then the mice were euthenazied, the organ tissue were performed pathological section and HE staining, observing the changes under microscope. Results: In the process of teratogenic toxicity test , comparing with control group ,the Placenta weight ,fetal mice weight , body len gth and tail length of mice fetal in adenovirus treated group did not reveal any alteration. Comparing with PBS group, there is no obvious change in skeleton of fetal mice treated with adenovirus. During the development process of F1 mice treated with adenovirus, the changes of mice weight show statistical significance. Howerer, in the progress of growth curve, this difference is not very obvious. Furthermore, the pathological section showed no obvious alteration in major organs. Conclusion: Our study demonstrated that bladder cancer specific adenovirus Ad-PSCAE-UPII-E1A-AR appear safe in the pregnant mice without any discernable effects on fetal mice and F1 development. Hence, It is a relatively safe for tumor gene therapy.
- Open Access
A Novel Primer Probe Set for Detection of SARS-CoV-2 by Sensitive Droplet Digital PCR
Background The current increase in the spread of (SARS-CoV-2) critically needs a multitarget diagnostic assays to promote analytical sensitivity to facilitate the public health actions. Objective The aim of this study was to develop a new primer-probe set targeting N gene of SARS-CoV-2 to improve the sensitivity for detection of COVID-19(Corona Virus Disease 2019)in multiplex rRT-PCR (Reversetranscript Realtime PCR) and ddPCR (Droplet Digital PCR). Results We designed primers/probes set N(LZU3) targeting the N gene of 2019-nCov and proved its sensitivity in both rRT-PCR and ddPCR. When the quantity of template was 105 copies/reaction, the mean Ct value of N(LZU3) was 32.563, the detection rate was 91.7%. If the quantity of template was 52.5 copies/reaction, the mean Ct value of N(LZU3) was 33.835, and the detection rate was 83.3%, which were similar with that of N(CDC) and N(USA). The calculated lower limit of detection (LOD) of the new primer-probe set N(LZU3) used in rRT-PCR was 118 copies/reaction. We also did one-step ddPCR for detection the same serial dilution of RNA template. It shows good linearity for primer/probe sets N(LZU3). The calculated lower limit of detection (LOD) of N(LZU3) was 22.4 copies/reaction, which was 1.12 copies/ul. Conclusion The novel primer-probe set(LZU3) targeting N gene of SARS-CoV-2 could be both used in rRT-PCR and ddPCR with better sensitivity, furthermore, ddPCR method had higer sensitivity than rRT-PCR, hence it could significantly improve SARS-CoV-2 detection efficiency in low virus load and asymptomatic infection.
Open AccessA Novel Primer Probe Set for Detection of SARS-CoV-2 by Sensitive Droplet Digital PCR
Background The current increase in the spread of (SARS-CoV-2) critically needs a multitarget diagnostic assays to promote analytical sensitivity to facilitate the public health actions. Objective The aim of this study was to develop a new primer-probe set targeting N gene of SARS-CoV-2 to improve the sensitivity for detection of COVID-19(Corona Virus Disease 2019)in multiplex rRT-PCR (Reversetranscript Realtime PCR) and ddPCR (Droplet Digital PCR). Results We designed primers/probes set N(LZU3) targeting the N gene of 2019-nCov and proved its sensitivity in both rRT-PCR and ddPCR. When the quantity of template was 105 copies/reaction, the mean Ct value of N(LZU3) was 32.563, the detection rate was 91.7%. If the quantity of template was 52.5 copies/reaction, the mean Ct value of N(LZU3) was 33.835, and the detection rate was 83.3%, which were similar with that of N(CDC) and N(USA). The calculated lower limit of detection (LOD) of the new primer-probe set N(LZU3) used in rRT-PCR was 118 copies/reaction. We also did one-step ddPCR for detection the same serial dilution of RNA template. It shows good linearity for primer/probe sets N(LZU3). The calculated lower limit of detection (LOD) of N(LZU3) was 22.4 copies/reaction, which was 1.12 copies/ul. Conclusion The novel primer-probe set(LZU3) targeting N gene of SARS-CoV-2 could be both used in rRT-PCR and ddPCR with better sensitivity, furthermore, ddPCR method had higer sensitivity than rRT-PCR, hence it could significantly improve SARS-CoV-2 detection efficiency in low virus load and asymptomatic infection.